Research programme: allogeneic chimeric antigen receptor regulatory T cell therapies - Sangamo Therapeutics
Alternative Names: CAR-TREG - Sangamo Therapeutics; Renal Transplant (Allogeneic) - Sangamo TherapeuticsLatest Information Update: 16 Mar 2022
Price :
$50 *
At a glance
- Originator Sangamo Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies; Regulatory T lymphocyte cell therapies
- Mechanism of Action Immunomodulators; Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Transplant rejection
Most Recent Events
- 28 Feb 2022 Research programme: allogeneic chimeric antigen receptor regulatory T cell therapies - Sangamo Therapeutics is available for licensing as of 28 Feb 2022. https://www.sangamo.com/programs#collaborations
- 28 Feb 2022 Preclinical trials in Transplant rejection in USA (Parenteral) as of February 2022 (Sangamo Therapeutics pipeline, February 2022)